In last trading session, Adverum Biotechnologies Inc (NASDAQ:ADVM) saw 0.39 million shares changing hands with its beta currently measuring 0.68. Company’s recent per share price level of $2.12 trading at $0.07 or 3.17% at ring of the bell on the day assigns it a market valuation of $44.19M. That closing price of ADVM’s stock is at a discount of -378.3% from its 52-week high price of $10.14 and is indicating a premium of 16.04% from its 52-week low price of $1.78. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.63 million shares which gives us an average trading volume of 331.92K if we extend that period to 3-months.
For Adverum Biotechnologies Inc (ADVM), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.29. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -2.29 in the current quarter.
Adverum Biotechnologies Inc (NASDAQ:ADVM) trade information
Upright in the green during last session for gaining 3.17%, in the last five days ADVM remained trading in the red while hitting it’s week-highest on Monday, 05/12/25 when the stock touched $2.12 price level, adding 29.57% to its value on the day. Adverum Biotechnologies Inc’s shares saw a change of -54.71% in year-to-date performance and have moved -24.73% in past 5-day. Adverum Biotechnologies Inc (NASDAQ:ADVM) showed a performance of -29.03% in past 30-days. Number of shares sold short was 1.48 million shares which calculate 3.88 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 15 to the stock, which implies a rise of 85.87% to its current value. Analysts have been projecting 2 as a low price target for the stock while placing it at a high target of 28. It follows that stock’s current price would jump 5.66% in reaching the projected high whereas dropping to the targeted low would mean a gain of 5.66% for stock’s current value.
Adverum Biotechnologies Inc (ADVM) estimates and forecasts
This year revenue growth is estimated to fall -81.00% from the last financial year’s standing.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 8.03% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 8.28% while estimates for its earnings growth in next 5 years are of 12.12%.
Adverum Biotechnologies Inc (NASDAQ:ADVM)’s Major holders
Insiders are in possession of 13.34% of company’s total shares while institution are holding 77.91 percent of that, with stock having share float percentage of 89.90%. Investors also watch the number of corporate investors in a company very closely, which is 77.91% institutions for Adverum Biotechnologies Inc that are currently holding shares of the company. TCG CROSSOVER MANAGEMENT, LLC is the top institutional holder at ADVM for having 2.01 million shares of worth $13.78 million. And as of 2024-06-30, it was holding 12.1873 of the company’s outstanding shares.
The second largest institutional holder is BML CAPITAL MANAGEMENT, LLC, which was holding about 1.97 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.4284 of outstanding shares, having a total worth of $13.49 million.
On the other hand, Franklin Strategic Series-FRANKLIN BIOTECHNOLOGY DISCOVERY FUND and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Jan 31, 2025 , the former fund manager was holding 624.74 shares of worth $1.32 million or 2.99% of the total outstanding shares. The later fund manager was in possession of 586.25 shares on Dec 31, 2024 , making its stake of worth around $1.24 million in the company or a holder of 2.81% of company’s stock.
